机构：[1]Department of Hematology and Hematology Research Institute, West China Hospital, Sichuan University, Chengdu, People's Republic of China四川大学华西医院[2]State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University, Chengdu, People's Republic of China四川大学华西医院[3]Department of Laboratory Medicine, West China Hospital, Sichuan University, Chengdu, People's Republic of China四川大学华西医院[4]Department of Hematology, Guangyuan Central Hospital, Sichuan, People's Republic of China
‘1·3·5 project for disciplines
of excellence–Clinical
Research Incubation Project,
West China Hospital, Sichuan University’ and the Sichuan
Provincial Academic and Technical Support Funding
Project (2022YFS0191).
语种：
外文
PubmedID：
中科院(CAS)分区：
出版当年[2022]版：
大类|2 区医学
小类|2 区血液学
最新[2023]版：
大类|2 区医学
小类|2 区血液学
第一作者：
第一作者机构：[1]Department of Hematology and Hematology Research Institute, West China Hospital, Sichuan University, Chengdu, People's Republic of China
共同第一作者：
通讯作者：
通讯机构：[1]Department of Hematology and Hematology Research Institute, West China Hospital, Sichuan University, Chengdu, People's Republic of China[*1]Department of Hematology and Hematology Research Insititute, West China Hospital, Sichuan University, Guoxuexiang 37, Chengdu, P.R. China.
推荐引用方式(GB/T 7714)：
Li He,Xiang Xinrong,Ding Hong,et al.Differentiation therapy using low-dose venetoclax in a variant acute promyelocytic leukaemia carrying ZBTB16-RARA[J].British journal of haematology.2022,doi:10.1111/bjh.18476.
APA：
Li He,Xiang Xinrong,Ding Hong,Yu Jiang,Xu Juan...&Wu Yu.(2022).Differentiation therapy using low-dose venetoclax in a variant acute promyelocytic leukaemia carrying ZBTB16-RARA.British journal of haematology,,
MLA：
Li He,et al."Differentiation therapy using low-dose venetoclax in a variant acute promyelocytic leukaemia carrying ZBTB16-RARA".British journal of haematology .(2022)
医学